177 related articles for article (PubMed ID: 30465673)
1. Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy.
Xin J; Zhang K; Huang J; Luo X; Gong X; Yang Z; Lin H; Shan H; Gao J
Biomater Sci; 2018 Dec; 7(1):262-271. PubMed ID: 30465673
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
[No Abstract] [Full Text] [Related]
3. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
4. Double-crosslinked nanocomposite hydrogels for temporal control of drug dosing in combination therapy.
Wu C; Liu J; Zhai Z; Yang L; Tang X; Zhao L; Xu K; Zhong W
Acta Biomater; 2020 Apr; 106():278-288. PubMed ID: 32084599
[TBL] [Abstract][Full Text] [Related]
5. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Gatti L; Cossa G; Tinelli S; Carenini N; Arrighetti N; Pennati M; Cominetti D; De Cesare M; Zunino F; Zaffaroni N; Perego P
J Pharmacol Exp Ther; 2014 Mar; 348(3):360-71. PubMed ID: 24345465
[TBL] [Abstract][Full Text] [Related]
6. Macroporous organosilicon nanocomposites co-deliver Bcl2-converting peptide and chemotherapeutic agent for synergistic treatment against multidrug resistant cancer.
Xie J; Xu W; Wu Y; Niu B; Zhang X
Cancer Lett; 2020 Jan; 469():340-354. PubMed ID: 31629930
[TBL] [Abstract][Full Text] [Related]
7. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance.
Song W; Tang Z; Shen N; Yu H; Jia Y; Zhang D; Jiang J; He C; Tian H; Chen X
J Control Release; 2016 Jun; 231():94-102. PubMed ID: 26928530
[TBL] [Abstract][Full Text] [Related]
8. Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.
Miodragović Đ; Merlino A; Swindell EP; Bogachkov A; Ahn RW; Abuhadba S; Ferraro G; Marzo T; Mazar AP; Messori L; O'Halloran TV
J Am Chem Soc; 2019 Apr; 141(16):6453-6457. PubMed ID: 30943017
[TBL] [Abstract][Full Text] [Related]
9. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
10. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
Du S; Liu K; Gao P; Li Z; Zheng J
Life Sci; 2018 Nov; 212():182-193. PubMed ID: 30243648
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression.
Li X; Sun D; Zhao T; Zhang Z
Eur J Pharmacol; 2020 Apr; 872():172982. PubMed ID: 32017938
[TBL] [Abstract][Full Text] [Related]
12. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
[TBL] [Abstract][Full Text] [Related]
13. Reversal of Cisplatin Resistance in Ovarian Cancer by the Multitargeted Nanodrug Delivery System Tf-Mn-MOF@Nira@CDDP.
Liu Y; Wang Y; Guan X; Wu Q; Zhang M; Cui P; Wang C; Chen X; Meng X; Ma T
ACS Appl Mater Interfaces; 2023 Jun; 15(22):26484-26495. PubMed ID: 37218712
[TBL] [Abstract][Full Text] [Related]
14. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
[TBL] [Abstract][Full Text] [Related]
15. Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.
Liu Y; Gao F; Song W
Biomed Pharmacother; 2017 Apr; 88():342-348. PubMed ID: 28119236
[TBL] [Abstract][Full Text] [Related]
16. A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer.
Zhang Z; Su T; Han Y; Yang Z; Wei J; Jin L; Fan H
Drug Deliv; 2021 Dec; 28(1):1982-1994. PubMed ID: 34569406
[TBL] [Abstract][Full Text] [Related]
17. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
Li Y; Deng Y; Tian X; Ke H; Guo M; Zhu A; Yang T; Guo Z; Ge Z; Yang X; Chen H
ACS Nano; 2015 Oct; 9(10):9626-37. PubMed ID: 26365698
[TBL] [Abstract][Full Text] [Related]
18. Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review.
Fei W; Li C; Tao J; Cai X; Yao W; Ye Y; Zhang Y; Yao Y; Song Q; Li F; Zheng C
Int J Pharm; 2020 Jun; 583():119385. PubMed ID: 32376447
[TBL] [Abstract][Full Text] [Related]
19. Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells.
Qi K; Li Y; Huang K; Xiong X; Chuchu F; Zhang C; Weng W
Biomed Pharmacother; 2019 May; 113():108665. PubMed ID: 30889490
[TBL] [Abstract][Full Text] [Related]
20. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells.
Liu H; Zhang Z; Chi X; Zhao Z; Huang D; Jin J; Gao J
Sci Rep; 2016 Aug; 6():31009. PubMed ID: 27484730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
